• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用病毒载体将基因转导到原代免疫细胞中的优化条件。

Optimized conditions for gene transduction into primary immune cells using viral vectors.

机构信息

Bio and Drug Discovery Division, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, PO Box 107, Daejeon, 34114, Republic of Korea.

Medicinal Chemistry and Pharmacology, Korea University of Science and Technology, Daejeon, 34316, Republic of Korea.

出版信息

Sci Rep. 2023 Jul 31;13(1):12365. doi: 10.1038/s41598-023-39597-2.

DOI:10.1038/s41598-023-39597-2
PMID:37524755
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10390464/
Abstract

Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising modality for anti-cancer treatment. Its efficacy is quite remarkable in hematological tumors. Owing to their excellent clinical results, gene- modified cell therapies, including T cells, natural killer (NK) cells, and macrophages, are being actively studied in both academia and industry. However, the protocol to make CAR immune cells is too complicated, so it is still unclear how to efficiently produce the potent CAR immune cells. To manufacture effective CAR immune cells, we need to be aware of not only how to obtain highly infective viral particles, but also how to transduce CAR genes into immune cells. In this paper, we provide detailed information on spinoculation, which is one of the best known protocols to transduce genes into immune cells, in a methodological view. Our data indicate that gene transduction is significantly dependent on speed and duration of centrifugation, concentration and number of viral particles, the concentration of polybrene, and number of infected immune cells. In addition, we investigated on the optimal polyethylene glycol (PEG) solution to concentrate the viral supernatant and the optimized DNA ratios transfected into 293T cells to produce high titer of viral particles. This study provides useful information for practical production of the gene-modified immune cells using viral vectors.

摘要

嵌合抗原受体 (CAR) T 细胞疗法已成为癌症治疗的一种有前途的方法。它在血液肿瘤中的疗效非常显著。由于其出色的临床结果,包括 T 细胞、自然杀伤 (NK) 细胞和巨噬细胞在内的基因修饰细胞疗法正在学术界和工业界得到积极研究。然而,制造 CAR 免疫细胞的方案过于复杂,因此仍不清楚如何有效地产生有效的 CAR 免疫细胞。为了制造有效的 CAR 免疫细胞,我们不仅需要了解如何获得高感染力的病毒颗粒,还需要了解如何将 CAR 基因转导到免疫细胞中。在本文中,我们从方法学的角度详细介绍了一种众所周知的将基因转导到免疫细胞中的方法——转染。我们的数据表明,基因转导显著依赖于离心的速度和持续时间、病毒颗粒的浓度和数量、聚凝胺的浓度以及感染的免疫细胞的数量。此外,我们还研究了浓缩病毒上清液的最佳聚乙二醇 (PEG) 溶液以及转染 293T 细胞的优化 DNA 比例,以产生高滴度的病毒颗粒。这项研究为使用病毒载体实际生产基因修饰的免疫细胞提供了有用的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/00700ac3f8ac/41598_2023_39597_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/458a6c7da485/41598_2023_39597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/7d904d9b882a/41598_2023_39597_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/54b5eda90857/41598_2023_39597_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/afdd439cc771/41598_2023_39597_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/39b4418ab970/41598_2023_39597_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/5ac4057b871c/41598_2023_39597_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/00700ac3f8ac/41598_2023_39597_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/458a6c7da485/41598_2023_39597_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/7d904d9b882a/41598_2023_39597_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/54b5eda90857/41598_2023_39597_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/afdd439cc771/41598_2023_39597_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/39b4418ab970/41598_2023_39597_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/5ac4057b871c/41598_2023_39597_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b10/10390464/00700ac3f8ac/41598_2023_39597_Fig7_HTML.jpg

相似文献

1
Optimized conditions for gene transduction into primary immune cells using viral vectors.使用病毒载体将基因转导到原代免疫细胞中的优化条件。
Sci Rep. 2023 Jul 31;13(1):12365. doi: 10.1038/s41598-023-39597-2.
2
Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.携带抗 Her2 嵌合抗原受体基因的重组慢病毒生产方案的比较分析与优化。
J Gene Med. 2018 Jul;20(7-8):e3027. doi: 10.1002/jgm.3027. Epub 2018 Jul 6.
3
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.慢病毒和阿尔法逆转录病毒工程化 CD19 特异性嵌合抗原受体自然杀伤细胞对急性淋巴细胞白血病的高效细胞毒性。
Front Immunol. 2020 Jan 24;10:3123. doi: 10.3389/fimmu.2019.03123. eCollection 2019.
4
Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells.棘突融合蛋白和 retronectin 可显著提高人源原发性 T 细胞中 Mucin-1 特异性嵌合抗原受体 (CAR) 的基因转导效率。
BMC Mol Cell Biol. 2021 Nov 23;22(1):57. doi: 10.1186/s12860-021-00397-z.
5
Non-industrial production of therapeutic lentiviral vectors: How to provide vectors to academic CAR-T.非工业生产的治疗性慢病毒载体:如何为学术 CAR-T 提供载体。
Biotechnol Bioeng. 2024 Oct;121(10):3252-3268. doi: 10.1002/bit.28794. Epub 2024 Jul 4.
6
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.利用细胞和基因组修饰技术来生成改良的“现货”CAR T 和 CAR NK 细胞。
Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020.
7
Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.使用γ逆转录病毒载体生成嵌合抗原受体T细胞。
Methods Mol Biol. 2020;2086:119-130. doi: 10.1007/978-1-0716-0146-4_8.
8
Generation of CAR-T Cells for Cancer Immunotherapy.用于癌症免疫治疗的嵌合抗原受体T细胞的生成。
Methods Mol Biol. 2019;1884:349-360. doi: 10.1007/978-1-4939-8885-3_24.
9
CAR-NK Cells: From Natural Basis to Design for Kill.嵌合抗原受体自然杀伤细胞:从天然基础到杀伤设计。
Front Immunol. 2021 Dec 14;12:707542. doi: 10.3389/fimmu.2021.707542. eCollection 2021.
10
Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.基因工程与人类自然杀伤细胞的扩增用于 CAR 增强免疫治疗血液系统恶性肿瘤。
Front Immunol. 2022 Apr 7;13:847008. doi: 10.3389/fimmu.2022.847008. eCollection 2022.

引用本文的文献

1
Anti-Her2 CAR-NK92 Cells and Their Exosomes: Generation, Characterization, and Selective Cytotoxicity Against Her2-Positive Tumor Cells.抗Her2嵌合抗原受体自然杀伤细胞系NK92及其外泌体:生成、表征及对Her2阳性肿瘤细胞的选择性细胞毒性
Int J Mol Sci. 2025 Aug 7;26(15):7648. doi: 10.3390/ijms26157648.
2
Immune Control of AIDS Progression by an Adenovirus-Based Therapeutic Vaccination in Acute Simian Immunodeficiency Virus-Infected Macaques.基于腺病毒的治疗性疫苗对急性感染猿猴免疫缺陷病毒的猕猴艾滋病进展的免疫控制
MedComm (2020). 2025 Aug 1;6(8):e70309. doi: 10.1002/mco2.70309. eCollection 2025 Aug.
3
Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities.

本文引用的文献

1
High efficiency closed-system gene transfer using automated spinoculation.利用自动化旋转接种技术实现高效封闭式基因转移。
J Transl Med. 2021 Nov 24;19(1):474. doi: 10.1186/s12967-021-03126-4.
2
Spinoculation and retronectin highly enhance the gene transduction efficiency of Mucin-1-specific chimeric antigen receptor (CAR) in human primary T cells.棘突融合蛋白和 retronectin 可显著提高人源原发性 T 细胞中 Mucin-1 特异性嵌合抗原受体 (CAR) 的基因转导效率。
BMC Mol Cell Biol. 2021 Nov 23;22(1):57. doi: 10.1186/s12860-021-00397-z.
3
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
治疗性结直肠癌疫苗:新兴模式与转化机遇
Vaccines (Basel). 2025 Jun 26;13(7):689. doi: 10.3390/vaccines13070689.
4
High-throughput High Content Quantification of HIV-1 Viral Infectious Output.HIV-1病毒感染性产出的高通量高内涵定量分析
bioRxiv. 2025 Jul 1:2025.06.28.662157. doi: 10.1101/2025.06.28.662157.
5
Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.用编码嵌合抗原受体的狒狒包膜假型慢病毒载体转导γδ T细胞,用于转化研究和临床应用。
Front Immunol. 2025 Jun 6;16:1548630. doi: 10.3389/fimmu.2025.1548630. eCollection 2025.
6
Engineered CAR-NK Cells for Cancer Immunotherapy: Lentiviral-Based CAR Transduction of NK-92 Cells.用于癌症免疫治疗的工程化嵌合抗原受体自然杀伤细胞:基于慢病毒的NK-92细胞嵌合抗原受体转导
Methods Mol Biol. 2025;2930:267-275. doi: 10.1007/978-1-0716-4558-1_19.
7
Integrated ATAC-seq and RNA-seq analysis identifies key regulatory elements in NK cells activated with feeder cells and IL-2.整合的ATAC-seq和RNA-seq分析鉴定了在用饲养细胞和白细胞介素-2激活的自然杀伤细胞中的关键调控元件。
Bioeng Transl Med. 2025 Feb 26;10(3):e10747. doi: 10.1002/btm2.10747. eCollection 2025 May.
8
Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations.优化免疫细胞治疗生产中的病毒转导:关键工艺设计考量
J Transl Med. 2025 May 2;23(1):501. doi: 10.1186/s12967-025-06524-0.
9
CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma.嵌合抗原受体自然杀伤细胞(CAR-NK)疗法联合检查点抑制可在胶质母细胞瘤中诱导NKT细胞反应。
Br J Cancer. 2025 May;132(9):849-860. doi: 10.1038/s41416-025-02977-8. Epub 2025 Mar 18.
10
Protocol for the simultaneous activation and lentiviral transduction of primary human T cells with artificial T cell receptors.用人造T细胞受体同时激活和慢病毒转导原代人T细胞的方案
STAR Protoc. 2025 Mar 21;6(1):103685. doi: 10.1016/j.xpro.2025.103685. Epub 2025 Mar 10.
抗 CD19 嵌合抗原受体 T 细胞疗法的长期随访。
J Clin Oncol. 2020 Nov 10;38(32):3805-3815. doi: 10.1200/JCO.20.01467. Epub 2020 Oct 6.
4
Lentivirus Manufacturing Process for Primary T-Cell Biofactory Production.用于原代T细胞生物工厂生产的慢病毒制造工艺
Adv Biosyst. 2020 Jun;4(6):e1900288. doi: 10.1002/adbi.201900288. Epub 2020 May 10.
5
Human chimeric antigen receptor macrophages for cancer immunotherapy.用于癌症免疫疗法的人嵌合抗原受体巨噬细胞。
Nat Biotechnol. 2020 Aug;38(8):947-953. doi: 10.1038/s41587-020-0462-y. Epub 2020 Mar 23.
6
High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.慢病毒和阿尔法逆转录病毒工程化 CD19 特异性嵌合抗原受体自然杀伤细胞对急性淋巴细胞白血病的高效细胞毒性。
Front Immunol. 2020 Jan 24;10:3123. doi: 10.3389/fimmu.2019.03123. eCollection 2019.
7
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
8
Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector.用绢毛猴包膜假型慢病毒载体高效且稳健地转导 NK 细胞。
Front Immunol. 2019 Dec 16;10:2873. doi: 10.3389/fimmu.2019.02873. eCollection 2019.
9
Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion.转座子介导的 CAR-T 细胞生成在体外扩增后显示出高效的抗 B 细胞白血病反应。
Gene Ther. 2020 Feb;27(1-2):85-95. doi: 10.1038/s41434-020-0121-4. Epub 2020 Jan 9.
10
Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies.建立一个用于CAR-T细胞生成与扩增的简单高效平台:从慢病毒生产到体内研究。
Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):150-158. doi: 10.1016/j.htct.2019.06.007. Epub 2019 Oct 9.